Skip to content
OpenCapital
Get started

The Oncology Institute, Inc. TOI Operating Lease Liability Payments - 2026 (Lessee)

Operating Lease Liability Payments - 2026 (Lessee) at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1.49M0.0%

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%—

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s operating lease liability payments - 2026 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s operating lease liability payments - 2026 (lessee)?
The Oncology Institute, Inc. (TOI) reported operating lease liability payments - 2026 (lessee) of $4.57M in Q1 2026.
How has The Oncology Institute, Inc.'s operating lease liability payments - 2026 (lessee) changed year-over-year?
The Oncology Institute, Inc.'s operating lease liability payments - 2026 (lessee) decreased by 6.5% year-over-year, from $4.89M to $4.57M.
What does operating lease liability payments - 2026 (lessee) mean?
This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.